Company Profiles

driven by the PitchBook Platform

Permeon Biologics

Description

Developer of therapeutic drugs using intracellular biologics. The company develops a panel of proprietary human proteins that exhibit potent activity for intracellular biologics in vivo and also creates active therapeutic agents with potent intracellular activity without cytotoxicity. The company's Intraphilin Technology Platform also enables functional proteins to replace or restore defective pathways inside cells that cause disease.

2008

Founded

PRIVATE

Status

Series A1

Latest Deal Type

$3.39M

Latest Deal Amount

$12M

Total Amount Raised

2

Investors

Description

Developer of therapeutic drugs using intracellular biologics. The company develops a panel of proprietary human proteins that exhibit potent activity for intracellular biologics in vivo and also creates active therapeutic agents with potent intracellular activity without cytotoxicity. The company's Intraphilin Technology Platform also enables functional proteins to replace or restore defective pathways inside cells that cause disease.

Website:

www.permeonbio.com

Formerly Known As

Newco LS15

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

One Kendall Square Building 1400 West, Suite 14203 Cambridge, MA 02139United States +1 (617) 945-7780
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Permeon Biologics's full profile, request a free trial.

    Permeon Biologics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Permeon Biologics Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Permeon Biologics Investors (2)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    ARCH Venture PartnersVenture CapitalMinority000 0000000 0000
    Flagship VenturesVenture CapitalMinority000 0000000 0000
    ARCH Venture Partners Venture Capital
    Flagship Ventures Venture Capital

    Permeon Biologics Executive Team (1)

    NameTitleBoard
    Seat
    Contact
    Info
    John RippleChief Executive Officer
    John Ripple Chief Executive Officer

    Permeon Biologics Board Members (7)

    NameRepresentingRoleSinceContact
    Info
    David Berry Ph.DFlagship VenturesGeneral Partner000 0000
    David LiuSelfChairman000 0000
    Douglas Cole MDFlagship VenturesGeneral Partner & Managing Partner000 0000
    Keith CrandellARCH Venture PartnersCo-Founder & Managing Director000 0000
    Noubar Afeyan Ph.DFlagship VenturesCo-Founder, Senior Managing Partner & Chief Executive Officer000 0000
    David Berry Ph.D General Partner Flagship Ventures
    David Liu Chairman Self
    Douglas Cole MD General Partner & Managing Partner Flagship Ventures
    Keith Crandell Co-Founder & Managing Director ARCH Venture Partners
    Noubar Afeyan Ph.D Co-Founder, Senior Managing Partner & Chief Executive Officer Flagship Ventures
    Request full access to PitchBook